Elektra (Dexketoprofen) may be part of symptomatic management and is commonly used to help manage symptoms related to physical discomfort. It generally provides supportive relief across conditions presenting with acute or disruptive episodes. As a non-steroidal anti-inflammatory drug (NSAID), its primary action may assist with easing discomfort.

The application of this substance may be part of symptomatic management applied in addressing pain of mild to moderate intensity. It helps ease discomfort associated with symptoms of increased neurological or muscular activity such as musculoskeletal pain, dental pain, and dysmenorrhoea (menstrual pain). The medication is often used when short-term symptomatic assistance is needed, relevant in contexts involving heightened systemic burden.

This approach assists with maintaining functional stability and contributes to improved comfort during symptomatic periods. The primary indication is relevant for easing symptoms related to physical discomfort: “symptomatic treatment of pain of mild to moderate intensity.”

Quick Fact: Supportive assistance for Symptoms that Create Noticeable Physiological Strain

Regulatory References

1. Rwanda FDA Summary of Product Characteristics for Ketesse (Dexketoprofen)

The official regulatory profile for Elektra (Dexketoprofen), an NSAID, defines population eligibility based on underlying health status, organ function, and age.

Absolute Prohibitions (Contraindications)

Use is strictly prohibited for patients with:

• Known hypersensitivity to Dexketoprofen or any other NSAID.
• Severe organ impairment, including severe heart failure, moderate to severe renal dysfunction (creatinine clearance leq 59 ml/min), or severely impaired hepatic function.
• Active or history of gastrointestinal bleeding or peptic ulcers.
• Crohn's disease, ulcerative colitis, active bleeding disorders, or severe dehydration.
• Pregnancy (third trimester) and lactation (breastfeeding).

---

Age- and Condition-Based Restrictions

• Pediatric Use: Safety and efficacy have not been established in children and adolescents; use is officially not recommended.
• Older Adults (Elderly): Although eligible, treatment must commence on the lowest available dose due to an increased risk of adverse reactions.
• Mild Organ Impairment: Patients with mild renal or hepatic dysfunction are eligible but require specific dose reduction and close clinical monitoring.
• Cardiovascular Caution: Use requires special caution and monitoring in patients with conditions like uncontrolled hypertension, mild to moderate heart failure, or established ischaemic heart disease.

Interactions with other medicines and products

The regulatory interaction profile for Dexketoprofen is primarily defined by the inherent class effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs). Co-administration with other NSAIDs, including COX-2 selective inhibitors, must be avoided. Use is formally contraindicated with high-dose Acetylsalicylic Acid in patients with a history of NSAID-induced hypersensitivity reactions.

A key pharmacodynamic risk is the potential for increased bleeding and ulceration. Co-use is not recommended with Anticoagulants (such as Warfarin) or Heparins due to interference with haemostasis. This additive risk also applies to co-administration with Oral Corticosteroids, Anti-platelet agents, and Selective Serotonin-Reuptake Inhibitors (SSRIs). Alcohol consumption is also associated with an increased risk of gastrointestinal bleeding.

Pharmacokinetic/Renal interactions indicate a risk of kidney function deterioration. Combining with Diuretics, ACE Inhibitors, or Aliskiren is associated with nephrotoxicity. Furthermore, Dexketoprofen may elevate plasma levels and increase the toxicity of agents such as Lithium and high-dose Methotrexate due to reduced clearance.

For the oral tablet, Food delays the rate of absorption; therefore, if rapid effect is required, administration at least 30 minutes before food is advised to mitigate this delay. Elderly patients and those with renal impairment are noted to have a greater susceptibility to adverse outcomes from these interactions.

️ Pharmacodynamic Mechanism

The mechanism of action is based on the chemical interruption of key prostanoid synthesis pathways, which subsequently modulates nociceptive signaling and hypothalamic thermoregulation. Dexketoprofen acts as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically the COX-1 and COX-2 isoforms. This enzymatic blockade halts the conversion of arachidonic acid, a precursor, into potent eicosanoid mediators, primarily prostaglandins ( PGE2).

Signaling Modulation

The resulting reduction in PGE2 concentration decreases the sensitization of peripheral nociceptors (pain-sensing nerve endings), thereby suppressing the transmission threshold of nociceptive impulses. The same reduction of prostanoids within the central nervous system (hypothalamus) modulates the elevated core thermoregulatory set point.

Onset Kinetics

The drug is delivered as the highly soluble salt of the single, pharmacologically active S-(+)-enantiomer. This purity and rapid absorption ensure the swift delivery of the active molecule to the COX enzyme targets, directly facilitating the rapid engagement of pathway inhibition.

Official Administration Guidelines

Dexketoprofen is administered through multiple official routes, typically the oral route (tablets or granules) or the parenteral route (intravenous or intramuscular injection) for acute care. The dosage regimen is highly regulated and depends on the formulation used. The standard oral dose is 12.5 mg or 25 mg per administration, with the 25 mg dose typically taken every 8 hours. A strict 75 mg maximum total daily dose applies to oral use.

For parenteral use, a standard dose of 50 mg is administered, often repeated every 8 to 12 hours. Specific procedural conditions govern administration, requiring the solution for injection to be delivered either as a quick intravenous bolus (over 15 seconds) or as a slow infusion over 10 to 30 minutes.

Administration of the substance is characterized by specific parameters for timing and duration. Oral preparations are typically taken at least 30 minutes before meals to achieve a faster effect. Use is exclusively short-term, limited to the symptomatic period for which it is prescribed. The parenteral route, used for acute pain management, is generally limited to two consecutive days of use. Furthermore, specific adjustments are established for certain groups; for older adults, treatment is initiated at the lowest recommended dose, with the daily maximum generally restricted to 50 mg.

Research Evidence / Overview of Studies

This section summarizes the published research that has evaluated the compound. It is provided for informational purposes only.

---

Mechanism of Action Studies

Studies investigated the relationship between the compound and specific cell receptors to understand if this relationship was associated with observed physiological changes. Studies investigated the relationship between the compound and inflammatory pathways and nerve signal transmission. Research findings reported observations regarding the production of certain neurotransmitters in preclinical models following compound administration.

---

Clinical Trials on Pain Management

A series of randomized, controlled trials (RCTs) has been the primary source of clinical data. These trials focused on adults experiencing chronic nerve pain or localized musculoskeletal discomfort.

Reduction in Pain Intensity

• Phase 3 RCTs: A multi-site Phase 3 study with 850 participants was examined for its potential to affect scores on the Visual Analog Scale (VAS) for pain intensity over a 12-week period. The results indicated variability in individual responses, with changes in scores observed at the conclusion of the study for some participants.
• Long-Term Follow-up: A separate open-label extension study investigated a potential reduction in chronic pain and examined whether the compound resulted in short-term or continuing changes in participants’ self-reported quality of life metrics over six months.

Impact on Mobility and Quality of Life

Research examined whether the compound affected the ability of participants to perform daily activities. Data from patient-reported outcome measures (PROMs) were collected to evaluate perceived limitations in movement and overall well-being. Findings evaluated outcomes based on baseline characteristics and adherence to the study protocol.

---

Pharmacokinetic and Drug Interaction Research

Bioavailability and Absorption

Studies examined the pharmacokinetic profile of this combination, including the active ingredient’s oral absorption. Results from a study comparing different formulations of the compound were analyzed, with one specific formulation demonstrating higher average concentration levels in the plasma. Research protocols or study instructions detailed the administration conditions during the study period.

Tolerability and Long-Term Safety

Studies have examined the outcomes and tolerability for long-term use in adults. Data collected over one year of continuous use were analyzed for the frequency and severity of adverse events. The most frequently reported events were mild and generally transient, as reported in the study data.

Comparative Effectiveness Studies

One systematic review examined existing trial data where the compound was compared against a commonly prescribed first-line therapy for neuropathic pain. The review aimed to understand if the difference in outcomes and tolerability were reported between the two treatments. Evidence remains limited due to high heterogeneity among the pooled studies.

---

Summary Note

The compound has been the subject of research focused on pain and inflammation.

Common questions about Elektra (Dexketoprofen) (FAQ)

Q: What type of pain medication is Elektra (Dexketoprofen)?

Official documents classify Elektra (Dexketoprofen) as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its action is focused on reducing inflammation and pain. It is also noted as a non-narcotic analgesic.

Q: What is the main chemical difference between Elektra (Dexketoprofen) and regular ketoprofen?

According to official product information, Elektra (Dexketoprofen) is the (S)-enantiomer (or active isomer) of the drug ketoprofen. This means it is the pharmacologically active component of the full ketoprofen compound.

Q: Is Elektra (Dexketoprofen) classified as a narcotic or a steroid?

Regulatory documents classify Elektra as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is specifically noted to be a non-narcotic analgesic.

Q: What are the most common uses for Elektra, according to regulatory documents?

Official product indications state that Elektra is used for the short-term treatment of mild to moderate pain. This includes common conditions like musculoskeletal pain, dental pain, and painful periods (dysmenorrhoea).

Q: Can Elektra be used to help with menstrual cramps?

Yes, the official product indications explicitly include the treatment of dysmenorrhoea, which is the medical term for painful periods or menstrual cramps.

Q: Is it possible to become dependent on Elektra (Dexketoprofen)?

Official documents classify Elektra as a non-narcotic analgesic. As a member of the NSAID class, it is not associated with dependency or addiction risk.

Q: How quickly can a person expect Elektra (Dexketoprofen) to start working?

Clinical data and official information indicate that the onset of action for the oral dose is typically observed within 30 minutes.

Q: What is the typical duration of pain relief after taking one dose of Elektra?

The drug's plasma half-life, which is a measure of how long the medicine remains in the system, is approximately 4 to 6 hours. This figure is used to describe the general duration of the drug's presence in the body.

Q: Are there any studies on how long Elektra (Dexketoprofen) can be used safely?

Official administration guidelines state that use is exclusively short-term and limited to the symptomatic period. The parenteral (injection) route must not exceed two consecutive days of use, while oral use duration is defined by prescription within the short-term limit.

Q: Is Elektra effective for chronic conditions like arthritis, or is it better for acute injuries?

Official indications restrict its use to the short-term treatment of acute pain. It is not indicated for the long-term management of chronic conditions such as arthritis.

Q: Does the efficacy of Elektra (Dexketoprofen) change based on the type of pain?

Official product indications list specific types of pain for which the drug is used, including dental pain, musculoskeletal pain, and dysmenorrhoea (menstrual cramps). These are the specific types of acute pain for which the drug holds regulatory indication.

Q: Does long-term use of Elektra increase cardiovascular risks?

Yes, official warnings regarding the NSAID class state that the risk of serious cardiovascular events like heart attack and stroke is potentially increased with the prolonged use of these drugs. This is why use is restricted to the short-term.

Q: What are the most common stomach-related side effects listed for Elektra (Dexketoprofen)?

Common gastrointestinal side effects listed in regulatory documents include symptoms like indigestion, heartburn, and general abdominal discomfort. Other common digestive effects may include nausea, vomiting, and diarrhoea.

Q: Is diarrhea or constipation a frequently reported side effect of Elektra?

Official product documents list diarrhoea as a common side effect of Elektra (Dexketoprofen). Information regarding constipation as a common side effect is generally less noted in the product summary.

Q: What symptoms might indicate a serious stomach issue while using Elektra (Dexketoprofen)?

Official patient information notes that severe stomach pains, passing stools that are black or bloody, or vomiting blood are signs that require immediate review.

Q: Can Elektra (Dexketoprofen) affect blood pressure levels?

Official documents list pre-existing high blood pressure as a condition that prevents the use of the drug. Furthermore, increased blood pressure is a listed side effect associated with the NSAID class of medicines.

Q: Is it common to feel drowsy or dizzy after taking Elektra?

Official side effect listings show that dizziness and somnolence (a term for drowsiness) are common central nervous system effects associated with Elektra.

Q: What information exists about Elektra (Dexketoprofen) potentially affecting the kidneys?

Regulatory documents advise against using Elektra if a patient has pre-existing or severe kidney problems. This is because the drug, like other NSAIDs, can affect renal function, especially in vulnerable patients.

Q: Can Elektra (Dexketoprofen) cause allergic reactions such as a widespread rash?

Official product warnings include the potential for allergic reactions. Signs of an allergic reaction may include swelling around the face or mouth, or the development of an itchy skin rash.

Q: Are there reported side effects related to the liver when taking Elektra?

Official documents list pre-existing or severe liver problems as a contraindication for using the medicine. This is a standard precaution given the potential for NSAIDs to affect liver function.

Q: Is fluid retention or swelling a known side effect of Elektra (Dexketoprofen)?

Swelling (known medically as edema), particularly in the feet, fingers, or lower legs, is a potential side effect associated with the NSAID class of drugs. This indicates a possibility of fluid retention.

Q: Can Elektra (Dexketoprofen) potentially hide signs of an underlying infection?

Regulatory documents note that Elektra, like other NSAIDs, can mask the symptoms of infectious diseases, which is a noted risk.

Q: Why are older patients sometimes more susceptible to side effects from Elektra?

Official guidelines mandate that treatment for older adults must be initiated at the lowest recommended dose. This is due to the potential for older patients to have a higher risk of serious side effects and complications related to the medication.

Q: What are the official contraindications for using Elektra (Dexketoprofen)?

Official documents list several conditions that prevent use, known as contraindications. These include a history of stomach ulcers, inflammatory bowel disorders, severe organ problems (heart, kidney, liver), and blood clotting issues.

Q: Are there specific heart conditions that generally prevent the use of Elektra (Dexketoprofen)?

Yes, official information states that the drug should generally not be used if a patient has a pre-existing heart condition or a significant problem with their blood vessels or circulation.

Q: Does a history of stroke or heart attack affect eligibility for this medication?

Given the general warnings regarding the NSAID class risks and the contraindications related to blood vessel and circulation problems, a history of stroke or heart attack may affect a person's eligibility to use this medication.

Q: Is Elektra (Dexketoprofen) typically prescribed to children or adolescents under 18?

Official product information states that the safety and efficacy of the product have not been established in children and adolescents under 18 years of age. Therefore, the drug is not recommended for use in this population.

Q: Why is Elektra not recommended during the later stages of pregnancy?

During the third trimester of pregnancy, official warnings cite the risk of serious side effects in the fetus, including cardiopulmonary toxicity (affecting the heart and lungs) and renal dysfunction (affecting the kidneys).

Q: Is there official guidance on using Elektra (Dexketoprofen) while breastfeeding?

Official regulatory documents generally indicate that the drug is contraindicated or not recommended for use while breastfeeding. This is due to the potential for the drug to pass into breast milk.

Q: Can people with a history of stomach ulcers take Elektra?

No, official product documentation lists a history of a stomach or duodenal ulcer as a contraindication.

Q: Is it appropriate to use Elektra if a person has pre-existing high blood pressure?

High blood pressure that is not adequately controlled is listed as a contraindication in official documents. This is a condition that prohibits the use of the drug based on official documentation.

Q: Are patients with inflammatory bowel diseases like Crohn's eligible for Elektra?

No, an inflammatory bowel disorder such as Crohn's disease or ulcerative colitis is listed as a contraindication for using the drug.

Q: What does official information say about the effect of Elektra (Dexketoprofen) on fertility?

Official documents state that NSAIDs, including Elektra, may temporarily impair female fertility. They also note that this effect is expected to reverse once treatment is stopped.

Q: Can someone with asthma or a history of reactions to aspirin take Elektra (Dexketoprofen)?

No, the product is contraindicated in patients in whom similar substances (such as aspirin) have previously caused attacks of asthma or other serious allergic disorders.

Q: What is the official warning regarding combining Elektra (Dexketoprofen) with alcohol?

Official documents warn that combining the drug with alcohol may increase the intensity of side effects such as dizziness or drowsiness. Additionally, the parenteral (injection/infusion) solution contains ethanol (alcohol) and carries specific warnings regarding use in patients with alcoholism.

Q: Can Elektra be taken at the same time as other NSAIDs like naproxen or ibuprofen?

No, the official advice is that patients should not take Elektra with any other anti-inflammatory painkiller belonging to the NSAID class, such as naproxen or ibuprofen.

Q: What are the known risks of combining Elektra (Dexketoprofen) with blood-thinning medicines?

Official documents list blood clotting problems as a contraindication for use. Combining this drug with blood-thinning medicines can lead to an increased risk of serious bleeding due to the anti-platelet effect of NSAIDs.

Q: Is there an interaction between Elektra and low-dose aspirin regimens?

Official warnings state the drug is contraindicated if similar substances, such as aspirin, cause allergic reactions. This suggests caution is exercised when considering its use alongside low-dose aspirin regimens.

Q: Does Elektra (Dexketoprofen) interact with common over-the-counter cold and flu remedies?

Yes, patient information warns that some cold and flu remedies contain other anti-inflammatory painkillers (NSAIDs) and should not be taken together with Elektra.

Q: Does Elektra (Dexketoprofen) contain sodium?

The official excipients list shows that the parenteral formulation (the solution used for injection or infusion) contains sodium.

Official Storage and Disposal Instructions for Elektra (Dexketoprofen)

Official regulatory documents define specific requirements for storing and disposing of Dexketoprofen to ensure product integrity and public safety.

Storage Conditions

Requirement	Official Statement
Temperature	Do not store above 30 C (applies to certain pack types).
Light Protection	Keep blister packs in the outer carton to protect the medicine from light.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Rules

Expired or unused Elektra must be disposed of according to local guidelines, as instructed by governmental authorities. To protect the environment, the medicine must not be thrown away with household trash or via wastewater. Users should utilize a designated pharmaceutical waste or medicine take-back scheme.